GPCR Scale Advantage Leverage Design Pharmaceuticals' ultra high throughput multiplex GPCR screening platform to access a large portion of the GPCR target space that is underexplored by the industry. The platform pools hundreds of GPCR cell lines and uses NGS readouts, enabling function-focused hit discovery across small molecules, peptides, and antibody libraries. This modality agnostic approach supports off-target profiling and can be tailored to GPCR isoforms and mutant variants, offering potential collaboration or licensing opportunities for major pharma and biotech partners seeking faster, more comprehensive GPCR programs.

External CRO Potential Design Pharmaceuticals offers GPCR discovery services that can augment partners without in house GPCR screening capabilities. Their Cambridge, MA location places them in a dense biotech ecosystem, which is beneficial for joint programs. With a small, agile team, they can execute fast, flexible collaborations and early stage discovery programs, serving pharma and biotech clients seeking to reduce risk and shorten timelines.

In Cell Edge Functional in cell screening differentiates their platform from traditional binding assays by measuring drug target function in living cells, potentially improving hit relevance and reducing late stage failures. The platform can be adapted to GPCR variants and incorporates cell based readouts that enable assessment of on and off target effects across many targets simultaneously. This capability pairs with SAR workflows using cell free synthesis to accelerate lead optimization, offering an integrated service for end to end discovery.

Integrated SAR Capability They combine cell based pharmacology with cell free synthesis for SAR and biologics libraries, enabling rapid translation from hit to lead and giving customers access to SAR data alongside functional readouts. This integrated approach supports end to end discovery pipelines and can be a compelling value proposition for biotech teams seeking to de risk early programs or accelerate timelines, particularly in GPCR targeted drug discovery.

Strategic Growth Fit As an early stage company with modest funding and a small team, Design Pharmaceuticals represents an attractive partner for strategic collaborations and co development deals that provide access to capital and a path to scale the platform. Proximity to Cambridge's thriving biotech ecosystem and a clear focus on accelerating GPCR drug discovery positions them as a potential partner for large pharma seeking novel GPCR approaches, pipeline expansion, or platform licensing.